Tuesday, September 29, 2020
ADVT 
International

Virus vaccine put to final test in thousands of volunteers

Darpan News Desk The Canadian Press, 27 Jul, 2020
  • Virus vaccine put to final test in thousands of volunteers

The world’s biggest COVID-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government -- one of several candidates in the final stretch of the global vaccine race.

There’s still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna Inc., will really protect.

The needed proof: Volunteers won’t know if they’re getting the real shot or a dummy version. After two doses, scientists will closely track which group experiences more infections as they go about their daily routines, especially in areas where the virus still is spreading unchecked.

“Unfortunately for the United States of America, we have plenty of infections right now” to get that answer, NIH’s Dr. Anthony Fauci recently told The Associated Press.

Several other vaccines made by China and by Britain’s Oxford University earlier this month began smaller final-stage tests in Brazil and other hard-hit countries.

But the U.S. requires its own tests of any vaccine that might be used in the country and has set a high bar: Every month through fall, the government-funded COVID-19 Prevention Network will roll out a new study of a leading candidate -- each one with 30,000 newly recruited volunteers.

The massive studies aren't just to test if the shots work — they're needed to check each potential vaccine's safety. And following the same study rules will let scientists eventually compare all the shots.

Next up in August, the final study of the Oxford shot begins, followed by plans to test a candidate from Johnson & Johnson in September and Novavax in October -- if all goes according to schedule. Pfizer Inc. plans its own 30,000-person study this summer.

That’s a stunning number of people needed to roll up their sleeves for science. But in recent weeks, more than 150,000 Americans filled out an online registry signalling interest, said Dr. Larry Corey, a virologist with the Fred Hutchinson Cancer Research Institute in Seattle, who helps oversee the study sites.

“These trials need to be multigenerational, they need to be multiethnic, they need to reflect the diversity of the United States population,” Corey told a vaccine meeting last week. He stressed that it’s especially important to ensure enough Black and Hispanic participants as those populations are hard-hit by COVID-19.

It normally takes years to create a new vaccine from scratch, but scientists are setting speed records this time around, spurred by knowledge that vaccination is the world's best hope against the pandemic. The coronavirus wasn't even known to exist before late December, and vaccine makers sprang into action Jan. 10 when China shared the virus' genetic sequence.

Just 65 days later in March, the NIH-made vaccine was tested in people. The first recipient is encouraging others to volunteer now.

“We all feel so helpless right now. There’s very little that we can do to combat this virus. And being able to participate in this trial has given me a sense of, that I’m doing something,” Jennifer Haller of Seattle told the AP. “Be prepared for a lot of questions from your friends and family about how it’s going, and a lot of thank-you’s."

That first-stage study that included Haller and 44 others showed the shots revved up volunteers’ immune systems in ways scientists expect will be protective, with some minor side effects such as a brief fever, chills and pain at the injection site. Early testing of other leading candidates have had similarly encouraging results.

If everything goes right with the final studies, it still will take months for the first data to trickle in from the Moderna test, followed by the Oxford one.

Governments around the world are trying to stockpile millions of doses of those leading candidates so if and when regulators approve one or more vaccines, immunizations can begin immediately. But the first available doses will be rationed, presumably reserved for people at highest risk from the virus.

“We’re optimistic, cautiously optimistic” that the vaccine will work and that “toward the end of the year” there will be data to prove it, Dr. Stephen Hoge, president of Massachusetts-based Moderna, told a House subcommittee last week.

Until then, Haller, the volunteer vaccinated back in March, wears a mask in public and takes the same distancing precautions advised for everyone -- while hoping that one of the shots in the pipeline pans out.

“I don’t know what the chances are that this is the exact right vaccine. But thank goodness that there are so many others out there battling this right now,” she said.

MORE International ARTICLES

WATCH: US & China, The 21st Century Cold War?

WATCH: US & China, The 21st Century Cold War?

China orders US consulate in Chengdu to shut down as retaliation for Houston closure amid allegations of espionage.

WATCH: US & China, The 21st Century Cold War?

Silent spread of virus keeps scientists grasping for clues

Silent spread of virus keeps scientists grasping for clues

One of the great mysteries of the coronavirus is how quickly it rocketed around the world. It first flared in central China and, within three months, was on every continent but Antarctica, shutting down daily life for millions.

Silent spread of virus keeps scientists grasping for clues

Afghan teenager shoots 2 Taliban militia with AK-47 rifle as revenge for parents killing

Afghan teenager shoots 2 Taliban militia with AK-47 rifle as revenge for parents killing

A story of one Afghan girl is gaining widespread attention on social media. When the Taliban came to kill her parents, she took matters into her own hands, bursting from her home brandishing an AK-47 and killing two of the Taliban men. 

Afghan teenager shoots 2 Taliban militia with AK-47 rifle as revenge for parents killing

'I have to see': Trump threatens to linger longer, regardless of November vote

'I have to see': Trump threatens to linger longer, regardless of November vote

Because it's 2020, anyone anxious about this year's presidential election has a new problem to worry about: the possibility that a defeated Donald Trump won't be willing to leave the West Wing.

'I have to see': Trump threatens to linger longer, regardless of November vote

New York CBS reporter Nina Kapur passes away at 26 in a moped accident

New York CBS reporter Nina Kapur passes away at 26 in a moped accident

Some heartbreaking news a reporter of Indian origin who worked for New York’s CBS affiliate CBS2 was killed Saturday after falling from one of the rented mopeds that have become increasingly popular in a city still not keen on using traditional mass transit.

New York CBS reporter Nina Kapur passes away at 26 in a moped accident

UK makes a COVID vaccine that can trigger an immune response

UK makes a COVID vaccine that can trigger an immune response

The University of Oxford has developed a coronavirus vaccine that appears safe and can trigger the immune response. England has already ordered 100 million doses of the vaccine.

 

 

UK makes a COVID vaccine that can trigger an immune response

PrevNext